Get the Stockscreener App
6.85
2.00%
-0.14
After Hours:
6.85
Kyntra Bio Inc stock is traded at $6.85, with a volume of 5,961.
It is down -2.00% in the last 24 hours and down -4.06% over the past month.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
See More
Previous Close:
$6.99
Open:
$6.99
24h Volume:
5,961
Relative Volume:
0.26
Market Cap:
$27.73M
Revenue:
$6.44M
Net Income/Loss:
$-58.21M
P/E Ratio:
0.2191
EPS:
31.2684
Net Cash Flow:
$-4.86M
1W Performance:
+0.74%
1M Performance:
-4.06%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$6.85
$7.0721
1-Week Range:
$6.8201
$7.0721
52-Week Range:
$6.32
$9.58
Kyntra Bio Inc Stock (KYNB) Company Profile
Name
Kyntra Bio Inc
Sector
Industry
Phone
415-978-1200
Address
350 BAY STREET, SAN FRANCISCO
Compare KYNB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KYNB
Kyntra Bio Inc
|
6.85 | 28.30M | 6.44M | -58.21M | -4.86M | 31.27 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kyntra Bio Inc Stock (KYNB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-26-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-26-23 | Downgrade | Stifel | Buy → Hold |
| Jun-26-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-02-23 | Upgrade | Stifel | Hold → Buy |
| Jan-31-23 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-05-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-22-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-20-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-16-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-16-21 | Downgrade | Stifel | Buy → Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-07-21 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-21 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-02-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
| Oct-26-20 | Initiated | Raymond James | Underperform |
| Jul-10-20 | Resumed | Stifel | Buy |
View All
Kyntra Bio Inc Stock (KYNB) Latest News
KYNB Stock Price, Quote & Chart | KYNTRA BIO INC (NASDAQ:KYNB) - ChartMill
KYNB Technical Analysis | Trend, Signals & Chart Patterns | KYNTRA BIO INC (NASDAQ:KYNB) - ChartMill
Kyntra Bio CEO Thane Wettig buys $19,852 in stock - Investing.com India
Kyntra Bio CEO Thane Wettig buys $19,852 in stock By Investing.com - Investing.com Australia
KYNTRA BIO (KYNB) CEO Thane Wettig adds 2,800 shares in open-market buy - Stock Titan
What's Next for Kyntra Bio (KYNB) at $6.80? 2026-05-19Growth Picks - Newser
Kyntra Bio Rocked by CEO’s Sudden Insider Stock Sale - TipRanks
Kyntra Bio CEO Thane Wettig buys $19,852 in company stock By Investing.com - Investing.com Australia
Kyntra Bio CEO Thane Wettig buys $19,852 in company stock - Investing.com India
KYNTRA BIO (KYNB) CEO Thane Wettig purchases 2,800 shares at $7.09 - Stock Titan
Kyntra Bio (KYNB) Q1 2026 Earnings Transcript - AOL.com
Armistice Capital (FGEN) reports 400,000-share, 9.88% position (May 2026) - Stock Titan
Kyntra Bio (KYNB) Institutional Ownership 2026 - MarketBeat
Number of shareholders of Kyntra Bio, Inc. – NASDAQ:KYNB - TradingView
Number of shareholders of Kyntra Bio, Inc. – LSE:0IL8 - TradingView
Kyntra Bio (Nasdaq: KYNB) Q1 2026 results show higher revenue, ongoing R&D spend - Stock Titan
Kyntra Bio stock (US3156631046): Q1 2026 revenue rises to $3.7M amid pipeline advances - AD HOC NEWS
Kyntra Bio Inc. (KYNB) News, Articles, Events & Latest Updates - Stocktwits
Kyntra Bio Inc (KYNB) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic Advances Amidst Challenges - GuruFocus
Kyntra Bio targets Q4 2026 interim readout while extending cash runway into 2028 - MSN
Kyntra Bio (KYNB) reports Q1 loss, tops revenue estimates - MSN
Kyntra Bio, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:KYNB) 2026-05-11 - Seeking Alpha
KYNB: Revenue rose, expenses fell, and clinical milestones remain on track with cash runway into 2028 - TradingView
Is Kyntra Bio (KYNB) 31.3% Overvalued After Q1 2026 Earnings Bea - GuruFocus
KYNB: Revenue up, losses narrowed, and key clinical programs advancing with strong cash position - TradingView
Kyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Kyntra Bio (NASDAQ:KYNB) Q1 Revenue Surges 180% as EPS Miss Tempers After-Hours Gains - ChartMill
Kyntra Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Kyntra Bio: Q1 Earnings Snapshot - 10TV
Kyntra Bio : Reports First Quarter 2026 Financial Results - marketscreener.com
KYNB: Q1 2026 revenue rose to $3.7M, net loss narrowed, and key clinical trials advanced - TradingView
Kyntra Bio (NASDAQ: FGEN) Q1 2026 results, oncology pipeline and cash runway - Stock Titan
Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update - Yahoo! Finance Canada
MSN Money - MSN
Kyntra Bio Inc (KYNB) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic Advances ... By GuruFocus - Investing.com Canada
Kyntra Bio Inc expected to post a loss of $3.35 a shareEarnings Preview - TradingView
Kyntra Bio (KYNB) upgraded to buy: Here's what you should know - MSN
Earnings Preview: Kyntra Bio to Report Financial Results Post-market on May 11 - 富途牛牛
Kyntra Bio sets May 11 Q1 results release, 5 p.m. investor call - Stock Titan
Kyntra Bio to Report First Quarter 2026 Financial Results - GlobeNewswire
Kyntra Bio to report Q1 2026 financial results and host investor call on May 11 - Pluang
William Blair Maintains KYNTRA BIO INC(KYNB.US) With Hold Rating - 富途牛牛
Kyntra Bio Inc Stock (KYNB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):